Kornimate/medical-research-clean huggingface dataset:
effectiveness of the adding high fidelity simulation to the bleeding control course in regards to proper tourniquet placement amongst school personnel

Conditions: Tourniquet Placement; Wound Packing

Summary: this is a joint project by the white plains school district and white plains hospital regarding the training of over 66 school personnel regarding the american college of surgeons (acs) "stop the bleed" campaign for mass casualty incidents. this project developed from an outreach from white plains hospital and an interest from the white plains school district to work together to train staff in the event of a mass casualty incident / active shooter.

from january through june 2019, participants will be requested to attend one of six sessions that will be held at the hospital simulation center. participants will be randomized into 1 of 2 study arms. each participant that enters the b-con course will be randomized using a "random generator." at the start of the program, all participants will be explained the purpose of the research study and the two groups (control versus high fidelity). an option will be given for participants to be able to opt out. so that our participants all have the same opportunities afforded to their colleagues, we will also offer the control group the option to participate in the high fidelity simulation at the conclusion of the entire program. all groups will sit through the exact same b-con powerpoint presentation by trained stb instructors. this course includes the powerpoint presentation that reviews how to call for help, assess those affected, identify the location of life-threatening bleed, apply pressure, pack a wound and/or apply a tourniquet and when to do this. tourniquet placement is taught as is wound packing placement. participants will each be given tourniquets to practice alongside the instructor. the presentation will cover the first hour of the curriculum. this is considered to be the standard for this course. upon conclusion of the course, the control group and high fidelity group will be separated into two rooms based on their randomization. in groups of 2, participants will be trained in tourniquet placement, wound packing. the high fidelity group will have a simulation intervention in addition and the wound packing will be performed on a device that has biofeedback. upon conclusion of this one hour session, both groups will be tested on wound packing and tourniquet placement. they will again be tested 3-8 months later on retention for wound packing and tourniquet placement.

Eligibility criteria:
inclusion criteria: * any volunteer employee who is over the age of 18 that is a staff member at the white plains school district. exclusion criteria: * any participants who have prior hemorrhage control training. however, although excluded from the study, they are welcome to participate in the program
transpulmonary pressure measurements in intubated children with covid-19 respiratory failure

Conditions: COVID 19

Summary: the purpose of this study is to gather information to help doctors understand how covid-19 affects the lungs in children.


Eligibility criteria:
inclusion criteria: * patients 0-17 years of age, 10 kg or greater, with suspected or confirmed covid-19 respiratory failure requiring endotracheal intubation and mechanical ventilation admitted to mayo clinic hospital, st. mary's campus pediatric intensive care unit. exclusion criteria: * patients \<10 kg * patients with pre-existing chronic mechanical ventilation (chronic respiratory failure) * patients with known esophageal disease (strictures, known esophageal anatomic abnormalities) * patients with severe coagulopathy (for which placement of esophageal balloon or other gastric tube via nose or mouth is contraindicated) * patients who are pregnant (as determined by standard pregnancy testing criteria for pediatric icu admission).
brad arrhythmia induced by repeated succinylcholine during gynecological laparoscopic surgery

Conditions: Bradycardia

Summary: cardiac arrhythmias are a well-recognized complication of anesthesia for laparoscopy. the aim of this study was to evaluate the efficacy of atropine sulfate for prevention of brad arrhythmia induced by repeated succinylcholine during gynecological laparoscopic surgery.

120 candidates, asa 1 in the age range 18-40 years scheduled for elective diagnostic gynecological laparoscopic surgery were randomly assigned into 4 groups to receive either atropine sulfate or normal saline solution (as placebo).

Eligibility criteria:
inclusion criteria: * female patients 18-50 years scheduled for elective diagnostic gynecological laparoscopic surgery exclusion criteria: * cardiac * diabetes mellitus * thyroid disease * any endocrine disease

Keywords: atropine succinycholine laparoscopy gynecology
could a simple information booklet modify low back pain patients beliefs after lumbar discectomy?

Conditions: Back Pain

Summary: the purpose of this study is to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy.

a translation / back-translation of the your back operation was performed and a before / after prospective study was realized. main outcome assessment was the quebec questionnaire. demographic data, personal medical sciatica pain history, graduation of the whole subject were recorded. acceptability of the booklet was also measured.

Eligibility criteria:
inclusion criteria: * a common monoradicular sciatica on a slipped disc with a clinical radio agreement requiring a surgical treatment, after failure of an good ambulatory treatment carried out, one duration of evolution higher than four weeks at naive subjects of any rachidian intervention exclusion criteria: * people presenting a cruralgia, a secondary sciatica (epiduritis, osseous metastasis...) or without relationship with a slipped disc (spinal stenosis), an lesion biradicular, an horse tail syndrome, an important motor deficit (muscular testing \< 3) * cognitive, auditive, major visual disorders or any subject which does not have a good comprehension of spoken french and/or writing, or having recourse to a third for reading and supplementing a document * subjects presenting a peripheral neuropathy, a severe and evolved diabetes, a cardiac insufficiency, dialysed subject * people observing a treatment which included psychotropics for more than three months (other that light hypnotic) because of the disturbances of vigilance and memory

Keywords: information booklet low back beliefs education disc hernia discectomy a common monoradicular sciatica on a slipped disc with a clinical radio agreement requiring a surgical treatment carried out one duration of evolution higher than four weeks at naive subjects of any rachidian interventional treatment after failure of an good ambulatory
a study to investigate the procoagulant effect of tenecteplase (tnk-tpa), alteplase (rt-pa) and streptokinase (sk) administered to patients with acute myocardial infarction (ami)

Conditions: Myocardial Infarction

Summary: primary objective: to evaluate the procoagulant effect of tnk-tpa compared to rt-pa and streptokinase, administered to patients with ami, by measuring the concentration of tat at 2 hours after the start of treatment versus baseline values. secondary objective: change from baseline in concentration of tat at 6 and 24 hours; change from baseline in concentration of d-dimers, f1+2, pai-1, pap at 2, 6 and 24 hours. incidence of adverse events (ae's), in -hospital complications, major or minor bleedings and serious adverse events.


Eligibility criteria:
inclusion criteria: * onset of symptoms of ami within 6 hours from randomisation * a twelve-lead electrocardiogram (ecg) showing st-segment elevation ≥ 0.1 millivolt (mv) in two or more limb leads, or ≥ 0.2 mv in two or more contiguous precordial leads indicative of ami, or new left bundle-branch block * age ≥ 18 exclusion criteria: * hypertension defined as blood pressure \> 180/110 mmhg (systolic bp \> 180 mmhg and/or diastolic bp \> 110 mmhg) on repeated measurements during current admission prior to randomisation * use of abciximab (reopro®) within the preceding 7 days or eptifibatide (integrilin®) or tirofiban (aggrastat®) within the past 48 hours * use of heparin within the preceding 12 hours * current therapeutic oral anticoagulation * major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months * any minor head trauma and any other trauma occurring after the onset of the current myocardial infarction * any known history of stroke or transient ischemic attack or dementia * any known structural damage of the central nervous system * ruptured aortic aneurism * active bleeding * prolonged cardiopulmonary resuscitation (\> 10 minutes) in the previous two weeks * pregnancy or lactation, parturition within the previous 30 days. women of childbearing potential must have a negative pregnancy test * any known active participation in another investigative drug study or device protocol in the past 30 days * previous enrolment in this study * any other condition that the investigator feels would place the patient at increased risk if the investigational therapy were initiated * inability to follow the protocol and comply with follow-up requirements
characterization of phenotype and genotype of early onset enteropathies

Conditions: Inflammatory Bowel Disease

Summary: this study has been set up in order to characterize phenotypes and genotypes of patients with early onset enteropathies. in that goal, investigators will collect biological samples (mainly blood) of patients suffering from early onset enteropathies and their healthy relatives.

this study specifically aims at the genetic analysis of early onset enteropathies with the goal in mind to delineate human pathways necessary to maintain intestinal homeostasis despite the considerable density of microbes colonizing the distal part of the human intestine.

Eligibility criteria:
main inclusion criteria: * severe chronic enteropathy * patients developing their first symptoms within the first 6 years of life and, in priority within the first two years of life, or patients with a disease of later onset, in case of a familial history suggestive of inherited mutations notably in families comprising several affected members * or : be a patient's relative, even if presenting with enteropathy of later onset. main exclusion criteria: * subject having participated to any therapeutical clinical study in the 30 days preceding the inclusion in this study,

Keywords: early onset entheropathy
study of va combined with haag regimen in newly diagnosed intermediate and high-risk aml patients

Conditions: Intermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia

Summary: the purpose of this study is to evaluate the efficacy and safety of va combined with haag in the induction treatment of newly diagnosed acute myeloid leukemia.

this is a single-center, single-arm, prospective clinical study in newly diagnosed intermediate and high-risk aml patients. the patients will receive venetoclax, azacitidine combined with haag regimen in the induction treatment.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed intermediate and high-risk aml according to the who (2022) classification of acute myeloid leukemia (non-apl). 2. age 18-65. 3. ecog score: 0-2. 4. no history of previous chemotherapy or target therapy. 5. serum total bilirubin \<= 2 times the upper limit of normal (uln), alanine aminotransferase (alt) \<= 1.5 times uln, aspartate aminotransferase (ast) \<=1.5 times uln; 6. creatinine clearance rate \>=30 ml/min; 7. serum lipase \<= 1.5 times uln, amylase \<= 1.5 times uln; 8. capable to understand and willing to participate in this study, signed the informed consent form. exclusion criteria: 1. aml transformed with chronic myelogenous leukemia. 2. acute promyelocytic leukemia (type m3). 3. patients with a second malignancy requiring treatment. 4. patients with uncontrolled active infection. 5. patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade iii/iv cardiovascular dysfunction according to the new york heart association classification. 6. patients with hepatic and renal inadequacy: total serum bilirubin \>=2.0 mg/dl, ast \>=3 times uln, serum creatinine clearance (ccr) \<50 ml / min. 7. patients with arterial oxygen saturation (spo 2) was \<95%. 8. patients with hiv infection. 9. patients with active hepatitis b or hepatitis c infection. 10. patients with other commodities that the investigators considered not suitable for the enrollment.
physical activity pathway for patients with osteoarthritis in primary care (oa-pcp) (r33)

Conditions: Osteoarthritis

Summary: the purpose of this study is to test an osteoarthritis (oa) primary care physical activity care pathway (oa-pcp), a scalable intervention that includes: 1) a practical process for physical inactivity screening in primary care, 2) a brief, tailored physical activity (pa) counseling intervention via telephone, 3) connection of patients with community programs and other resources to support pa, and 4) follow-up with patients to deliver additional appropriate counseling and referrals to pa resources. this program will be compared to another program that provides education on a variety of topics important to understanding osteoarthritis (oa) and its care.

this study will be a randomized pilot trial of the refined oa-pcp among n=240 patients age ≥65 with hip and/or knee oa recruited from primary care clinics. participants will be assigned equally to either the oa-pcp or an attention control group. participants will complete assessments at baseline, and 6-month and 12-month follow-up. primary endpoint of the trial will be objectively assessed pa, measured via accelerometer and secondary endpoint will be self-reported pain and function.

Eligibility criteria:
inclusion criteria: * age 65 or older * one other chronic health condition that qualified under chronic care management (ccm) guidelines, including: diabetes, depression, hypertension, hyperlipidemia, heart failure, atrial fibrillation, ischemic heart disease, stroke/transient ischemic attack (tia), peripheral vascular disease, chronic obstructive pulmonary disease (copd), bronchiectasis, asthma, rheumatoid arthritis, osteoarthritis, hiv/aids, chronic kidney disease, hepatitis (chronic \& viral b \& c) and osteoporosis * current joint symptoms * self-reported physical activity \<150 minutes per week * willing to make a change in pa over the next 3 months exclusion criteria: * pain in chest when performing physical activity * pain in chest when not performing physical activity * loss of balance because of dizziness or loss of consciousness * recommendation from doctor to only perform physical activity under medical supervision * no documented diagnosis of knee or hip oa * dementia or other memory loss condition * active diagnosis of psychosis * active substance abuse disorder * total knee or hip replacement surgery, meniscus tear, ligament tear, or other significant lower extremity injury or surgery in the last 6 months * severe hearing or visual impairment * serious/terminal illness as indicated by referral to hospice or palliative care * unstable angina * hospitalization for cardiovascular event in last 6 months * history of ventricular tachycardia * unstable chronic obstructive pulmonary disease (2 hospitalizations within the previous 6 months and/or on oxygen) * stroke with moderate to severe aphasia * recent history (last 6 months) of three or more falls

Keywords: osteoarthritis knee osteoarthritis hip osteoarthritis
visualization and structured attention behaviour for pain and anxiety reduction during ablation of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to test the efficacy of visualization and relaxation exercises together with a structured behavioural attention from nurses during ablation of atrial fibrillation. the study will test the following hypothesis which is also aim for intervention: relaxation and visualization performed in patients during ablation of atrial fibrillation combined with structured attention behaviour from the nurse reduces the patient's experience of pain and anxiety - and secondary reduces the consumption of painkillers and the number of episodes of adverse outcome that requires extra attention from staff. the survey is conducted as a controlled trial with a control group and an intervention group.

background: atrial fibrillation (af) is the most common form of cardiac arrhythmia with a prevalence of 5% among people older than 65 years, and 0.4% of the total population. ablation is a relatively new treatment that has proven to be effective in removing physical symptoms in patients with severe symptoms. compared to other ablation treatments, ablation of af is complex and of longer duration. it can be accompanied by significant discomfort and pain, despite pharmacological analgesia. non pharmacological analgesia in the form of relaxation exercises and visualization has successfully been used to reduce the experience of pain intensity and anxiety of other invasive procedures. aim: the study will test the following hypothesis which also acts as aim for intervention: relaxation and visualization performed in patients during ablation of atrial fibrillation combined with structured attention behaviour from the nurse reduces the patient's experience of pain and anxiety - and secondary reduces the consumption of painkillers and the number of episodes of adverse outcome that requires extra attention from staff. design / methodology: the trial is conducted in a cardiac lab. the survey is conducted as a controlled trial. the control group receives conventional care and treatment and the intervention group receives visualization and relaxation exercises together with structured behavioural attention. the patient scores experienced pain intensity and anxiety in a validated linear numerical rank scale. a statistical calculation of power estimated the required number of patients to 70 in each group.

Eligibility criteria:
inclusion criteria: * patients referred for ablation of atrial fibrillation exclusion criteria: * unable to give informed consent * impaired mental function, psychosis, severe chronic obstructive pulmonary disease, intolerance towards midazolam or fentanyl * undergoing the ablation in general anaesthesia * unable to speak or understand danish

Keywords: visualization relaxation self hypnotic relaxation hypnosis invasive medical procedures atrial fibrillation ablation catheter ablation pain anxiety
assessment of digital breast tomosynthesis (dbt) in the screening environment

Conditions: Breast Abnormalities

Summary: the objective of this study is to demonstrate that digital breast tomosynthesis (dbt) in combination with full field digital mammography (ffdm) has the potential to reduce significantly baseline screening recall rates without a loss in the detection of cancers. the primary hypothesis of the study is that dbt in combination with ffdm will reduce baseline screening mammography recall rates in negative examinations by at least 20%.

the ffdm images and the ffdm images with the dbt images will be interpreted independently by two experienced radiologists under standard clinical screening procedures. recommended recall rates will be assessed and compared as a result of each of the two interpretations.

Eligibility criteria:
inclusion criteria: * women between the ages of 34 and 56. * women presenting for their baseline screening mammography examination exclusion criteria: * women with a palpable finding(s) via a breast self examination (bse) or clinical breast examination (cbe). * women who may be or are pregnant by self report * women older than 55 years of age or younger than 35. * women with known fatty breast tissue * males and children * women who are unable to understand or execute written informed consent

Keywords: digital breast tomosynthesis baseline screening mammography recall rates
individual dosing of levothyroxine after thyroidectomy

Conditions: Thyroid Neoplasms; Hypothyroidism; Surgery

Summary: recently, zaborek et al. raised a poisson regression model for levothyroxine(lt4) dosing scheme to predict individual dose of lt4 after thyroidectomy: daily lt4 dose=e\[2.02+0.01(w)-0.0037(a )-0.098(f)-0.01(b)+0.007(t)+0.108(i)-0.014(m), where w is the weight of the patient (kg), a is the age of the patient (years), and f is the gender (for women 1, male is 0), b represents the patient's body mass index (bmi), t represents the preoperative tsh level, i represents whether the patient takes iron preparations (1, if not 0), m represents whether the patient takes multivitamins/minerals (1, if not 0). we demonstrated its value with our retrospective data in our center. therefore, we intend to carry out this randomized controlled trial in order to further evaluate the model. the clinical significance of this method can provide a basis for the future use in clinical optimization of individualized dosing.

patients who underwent total/near-total thyroidectomy or completion thyroidectomy and require levothyroxine replacement therapy will be enrolled in this study. they will be randomized distributed into two groups. in one group, patients will be dosing lt4 according to weight-based algorithm, namely 1.6 μg /kg/d. in the other group, patients will be dosing lt4 according to the poisson regression model algorithm. they will be followed up 3-6 weeks after surgery for the first time. during the follow up, thyroid hormone will be tested and lt4 dosing will be adjusted accordingly. then, we compare patients in which group will achieve euthyroidism more quickly.

Eligibility criteria:
inclusion criteria: * patients underwent total/near-total thyroidectomy or completion thyroidectomy; patients with benign disease, or low-risk differentiated thyroid cancer, or medullary thyroid cancer who don't need tsh suppressive therapy; exclusion criteria: * patients with heart disease or severe liver/kidney insufficiency; patients taking liothyronine in addition to levothyroxine;

Keywords: levothyroxine thyroidectomy thyroid hormone replacement therapy individualized therapy regression model
a bronchoprovocation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of csj117 in adult subjects with mild atopic asthma

Conditions: Asthma

Summary: this is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study. approximately 55 subjects with mild stable atopic asthma who exhibit an ear and lar to a common inhaled allergen will receive multiple once daily doses of inhaled csj117 or placebo over 12 weeks. two sequential dose cohorts are planned for this study, cohort 1 and cohort 2. cohort 2 will be split into two parts, cohort 2a and 2b


Eligibility criteria:
inclusion criteria: * diagnosis of stable mild atopic asthma, as defined by the american thoracic society/ european respiratory society statement, who exhibit an early and late asthmatic response to a common inhaled allergen during the screening allergen inhalation challenge. * throughout the screening period and at baseline, only infrequent use of inhaled short-acting beta2-agonists (less than or equal to twice weekly) to treat asthma and/or prophylactic use prior to exercise. inhaled short-acting beta2-agonist must be withheld for 8 hours before spirometry. exclusion criteria: * hospitalization or emergency room treatment for acute asthma in the 6 months prior to screening or during the screening period. * any worsening or exacerbation of asthma (e.g., an event requiring a change in treatment) in the six weeks before screening or during the screening period. * a history of any clinically significant chronic pulmonary disease other than mild atopic asthma, including but not limited to copd, interstitial lung disease or bronchiectasis * use of immunosuppressive medications or allergen-specific immunotherapy within 6 months prior to screening.

Keywords: asthma allergen bronchoprovocation pharmacodynamics pharmacokinetics safety tolerability